(NASDAQ: OGI) Organigram Holdings's forecast annual revenue growth rate of 17.24% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.19%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Organigram Holdings's revenue in 2025 is $115,358,333.On average, 3 Wall Street analysts forecast OGI's revenue for 2025 to be $21,035,742,126, with the lowest OGI revenue forecast at $20,860,005,881, and the highest OGI revenue forecast at $21,256,137,834. On average, 3 Wall Street analysts forecast OGI's revenue for 2026 to be $24,526,118,798, with the lowest OGI revenue forecast at $23,489,110,946, and the highest OGI revenue forecast at $25,698,114,290.
In 2027, OGI is forecast to generate $28,453,376,028 in revenue, with the lowest revenue forecast at $28,453,376,028 and the highest revenue forecast at $28,453,376,028.